Information:
Fel:
ID
43819
Beskrivning
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01463072
Länk
https://clinicaltrials.gov/show/NCT01463072
Nyckelord
Versioner (2)
- 2016-03-13 2016-03-13 -
- 2021-09-20 2021-09-20 -
Uppladdad den
20 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Male Breast Cancer NCT01463072
Eligibility Male Breast Cancer NCT01463072
- StudyEvent: Eligibility
Similar models
Eligibility Male Breast Cancer NCT01463072
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
metastatic breast cancer
Item
locally advanced or metastatic breast cancer
boolean
C0278488 (UMLS CUI [1])
estrogen receptor; progesterone receptor ; human epidermal growth factor receptor 2
Item
any estrogen receptor (er), progesterone receptor (pr), or human epidermal growth factor receptor 2 (her2neu) status as long as the patient will receive nab-paclitaxel alone
boolean
C0034804 (UMLS CUI [1])
C0034833 (UMLS CUI [2])
C3496586 (UMLS CUI [3])
C0034833 (UMLS CUI [2])
C3496586 (UMLS CUI [3])
chemotherapy metastatic disease
Item
first or second line chemotherapy treatment for metastatic disease
boolean
C0392920 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
karnofsky performance scale
Item
karnofsky performance scale (kps) >= 70%
boolean
C0206065 (UMLS CUI [1])
toxicity alopecia
Item
resolution of grade >= 2 toxicity from prior therapy (other than alopecia)
boolean
C0013221 (UMLS CUI [1,1])
C0002170 (UMLS CUI [1,2])
C0002170 (UMLS CUI [1,2])
peripheral neuropathy
Item
peripheral neuropathy =< grade 1
boolean
C0031117 (UMLS CUI [1])
absolute neutrophil count
Item
absolute neutrophil count >= 1,500/mm^3
boolean
C0948762 (UMLS CUI [1])
platelets
Item
platelets >= 100,000 cells/mm^3
boolean
C0005821 (UMLS CUI [1])
hemoglobin
Item
hemoglobin (hb) >= 9.0 g/dl
boolean
C0518015 (UMLS CUI [1])
Aspartate aminotransferase/Alanine aminotransferase
Item
aspartate aminotransferase (ast) and alanine aminotransferase (alt) =< 2.5 x institutional upper limit of normal
boolean
C0805162 (UMLS CUI [1])
alkaline phosphatase
Item
alkaline phosphatase =< 2.5 x upper limit of normal unless bone metastasis are present in the absence of liver metastases
boolean
C0201850 (UMLS CUI [1])
bilirubin
Item
bilirubin =< 1.5 mg/dl
boolean
C0005437 (UMLS CUI [1])
creatinine clearance
Item
creatinine clearance (calculated or 24 hour) >= 30 ml/min
boolean
C0373595 (UMLS CUI [1])
informed consent
Item
ability to understand and the willingness to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])
Study Subject Participation Status
Item
patients may not be receiving any other investigational agents
boolean
C2348568 (UMLS CUI [1])
CNS metastases; dosage corticosteroids
Item
untreated central nervous system (cns) metastases or symptomatic cns metastases requiring escalating doses of corticosteroids
boolean
C0686377 (UMLS CUI [1])
C0178602 (UMLS CUI [2,1])
C0001617 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,1])
C0001617 (UMLS CUI [2,2])
hypersensitivity paclitaxel
Item
known history of allergic reactions to paclitaxel
boolean
C0020517 (UMLS CUI [1,1])
C0144576 (UMLS CUI [1,2])
C0144576 (UMLS CUI [1,2])
infection
Item
presence of any serious or uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
adjuvant therapy taxane
Item
receipt of a taxane for adjuvant therapy or metastatic disease in the last 12 months
boolean
C0677850 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
C0215136 (UMLS CUI [1,2])